Skip to content
DataLookout
Menu

NCT07801976

Positron Emission Tomography (PET) Imaging of Reactive Oxygen and Nitrogen Species: Human Observation of Retention and Safety of [18F]-Fluoroedaravone

StatusNot Yet Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 57 words
  2. Notable Start date pushed from Oct 2026 to Dec 2026
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Evaluate safety of [18F]fluoroedaravone administration in up to 10 human subjects.
Timeframe: Baseline at study entry and within 4 days following PET/CT.
Evaluate the biodistribution of [18F]fluoroedaravone in up to 10 human subjects.
Timeframe: Through study completion, with an average of 3 months post-PET/CT.

Arms and interventions

Treatment - [18F]Fluoroedaravone PET ImagingExperimental

Healthy adult volunteers receive a single intravenous injection of \[18F\]fluoroedaravone (\[18F\]FEDV), followed by serial whole-body PET/CT imaging evaluations. Participants also undergo blood collection, urine collection, vital sign monitoring, ECG assessments, symptom questionnaires, and a follow-up safety visit 48 to 96 hours after tracer administration.

Drugs: [18F]Fluoroedaravone ([18F]FEDV)

Procedures: PET/CT Imaging